Jobs
-
On March 10, 2016, the Philadelphia District Office of the FDA issued a warning letter to online retailer Dr Natural Healing about sales of epinephrine capsules packaged with a dry powder inhaler as a treatment… Read more . . .
-
Mundipharma has submitted a marketing application to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the flutiform fluticasone/formoterol K-Haler breath-activated MDI for the treatment of asthma, the company said. The submission will be… Read more . . .
-
According to Boehringer Ingelheim Pharmaceuticals, the FDA has approved a supplemental NDA for the Stiolto Respimat tiotropium/olodaterol SMI for a labeling change to add quality of life data obtained from the OTEMTO 1&2 studies. Stiolto… Read more . . .
-
Kamada has submitted a Marketing Authorization Application for its inhaled alpha-1 antitrypsin (AAT) therapy for the treatment of AAT deficiency to the European Medicines Agency, and the filing EMA has validated the application, the company… Read more . . .
-
The upcoming RDD meeting to be held April 17-21, 2016 at the Westin Kierland Resort in Phoenix, AZ will offer several new features in addition to the usual scientific presentations, posters, exhibition, and networking opportunities. For the… Read more . . .
-
Boehringer Ingelheim and Propeller Health have announced a new partnership that will allow COPD and asthma patients using Respimat inhalers “to enroll at select US health systems in a new program that is designed to… Read more . . .
-
The FDA has granted Qualified Infectious Disease Product (QIDP) designation to Raptor Pharmaceutical’s MP-376 inhaled levofloxacin for the treatment of chronic P. aeruginosa lung infections in patients with cystic fibrosis, non-cystic fibrosis bronchiectasis (BE), and… Read more . . .
-
A study published online ahead of print in the Annals of the American Thoracic Society (AnnalsATS) finds that a “teach-to-goal” inhaler education strategy reduced rescue inhaler misuse to 11% compared to 60% for a “brief… Read more . . .
-
Apotex has launched a generic version of Merck’s Nasonex mometasone furoate nasal spray in the United States, the company said. In June 2012, A US District Court judge upheld a Merck patent on mometasone furoate… Read more . . .
-
Verona Pharma has announced positive data from a Phase 2a study of RPL554, an inhaled PDE3/PDE4 inhibitor for the treatment of acute exacerbations in COPD patients. According to the company, asthma patients who received the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK